Arnold & Porter Kaye Scholer Llp
Professional Services |
Law Firms
Recent News About Arnold & Porter Kaye Scholer Llp
View More
-
Deal leaves 16 other elite universities to face claims they participated in a 'cabal' to limit financial aid awards to minimize competition for students
-
Plaintiffs claims tuition would've been cheaper but for an agreement among some of America's top colleges and universities, including University of Chicago, Northwestern, Notre Dame, Brown, Yale, Cal Tech, MIT and Duke, among others.
-
A class of consumers suing McDonald’s Corporation over the alleged presence of polyfluoroalkyl substances (PFAS) in wrappers argue that the case belongs in the Southern District of Illinois as it is the only case with an Illinois resident, who happens to live in Madison County.
-
Rockford has launched a lawsuit accusing Mallinckrodt of overcharging for a hormone treatment drug.
-
Judges said the jury award wasn't excessive, as woman claimed discontinued product left her with permanent injuries and pain.
-
A federal appeals court in Chicago could be tasked with taking another look at its previous decision undoing a jury verdict ordering drug maker GSK to pay $3 million to the widow of a Chicago lawyer who committed suicide after taking the generic equivalent of a widely prescribed antidepressant drug.
-
The U.S. Supreme Court is tackling the question of whether drug companies can be sued for not making their warning labels strong enough, even though the FDA controls the labels. But whether a forthcoming Supreme Court decision will affect a decision denying a $3 million judgment to the widow of a Chicago lawyer who committed suicide after taking the generic equivalent of Paxil remains unclear.
-
Asserting a Chicago federal appeals panel wrongly invalidated a jury’s verdict, attorneys for the widow of a Chicago lawyer who committed suicide after taking the generic version of the antidepressant drug Paxil, have asked the U.S. Supreme Court to throw out the appellate ruling and order more proceedings on whether pharmaceutical company GlaxoSmithKline should be made to pay for allegedly not revising their drug’s warning label to reflect an increased risk of suicide.
-
A Chicago federal appellate court has refused to reexamine its decision last month that reversed a $3 million verdict against drugmaker GlaxoSmithKline, on grounds the company was not responsible for the labeling of the generic version of its product Paxil, despite plaintiff’s urging a rehearing was needed, because she said the appeals panel set a “dangerous precedent.”
-
A federal appeals panel has tossed out a $3 million verdict vs GSK for the widow of a Chicago lawyer who committed suicide after taking the generic equivalent of GSK's drug, Paxil. The judges said the company can't be held responsible for language on the warning label when that language was controlled by the FDA.
-
A Chicago federal judge has barred an Ohio health insurer from pursuing a class action against several pharmaceutical companies, which are already embroiled in massive litigation over their testosterone drugs, saying the thousands of potential claims would be too individualized to be served well by a class action and the insurer’s drug review practices were “unconventional.”
-
The U.S. Supreme Court has decided to wade into the contentious question over whether a pharmaceutical company can be held liable for failing to warn consumers and doctors of a drug’s potential effects, potentially portending significant implications for a $3 million verdict a jury awarded to the widow of a Chicago lawyer who committed suicide in the Loop after taking the generic version of an antidepressant drug.
-
Mired in a long-running anti-trust class action brought by millions of merchants who seek billions of dollars in connection with credit card processing fees, Visa wants the Aldi food store chain, which several months ago adopted a policy accepting cards from customers, to turn over documents that will presumably show Aldi freely chose to honor Visa cards, despite allegations Visa tried to throttle competition.
-
With one judge saying he found “troubling” the potential harm to patients from decreased incentives for drug makers to develop new breakthrough medications, a federal appellate panel in Chicago hashed out some of the legal questions surrounding the appeal of jury’s verdict ordering GlaxoSmithKline to pay $3 million to the widow of a Chicago lawyer who committed suicide, and whose family has accused the pharmaceutical company of failing to warn that a generic version of its drug Paxil could raise a patient’s risk of suicide.
-
A DeVry University graduate has filed a putative class action in Cook County Circuit Court, alleging the nationwide electronics and business school has exaggerated the employment rates of graduates, so as to lure new students. The complaint is similar to a lawsuit from a different plaintiff and legal team now pending in federal court on the same claims.
-
Dunkin' Donuts will need to try again to poke holes in a lawsuit claiming it deceived consumers about how much blueberry is actually in a blueberry donut, after a Chicago federal judge refused to toss the class action.
-
A federal judge has tossed, with leave to amend, the bulk of a federal racketeering and fraud class action brought by an Ohio-based health insurer against Abbvie and other makers of testosterone drugs, saying the insurer has not yet backed up with enough particularity its allegations the drugmakers invented the condition known as “low T,” and, through false marketing to doctors, patients and insurers alike, induced insurers and others to pay far more for the drugs to treat the condition.
-
A federal judge has dismissed the state law counts in a massive lawsuit against eight manufacturers of testosterone replacement therapy drugs, agreeing with the defendants that the claims are preempted by federal law.U.S. District Judge Matthew F. Kennelly ruled Monday in federal court in Chicago in the multi-district litigation involving more than 2,500 plaintiffs who have alleged they’ve suffered injuries from improper prescribing of the testosterone replacement drugs.
